RBC Capital maintains Outperform rating on BeOne Medicines
RBC Capital reiterated an Outperform rating on BeOne Medicines, per a ratings-action report cited by Benzinga.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
RBC maintains Outperform on BeOne Medicines, raises PT to $459
RBC Capital maintained its Outperform rating on BeOne Medicines and raised its price target to $459.00 per share from $450.00.